Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04366050 · ClinicalTrials.gov registry record · Phase 2
Ramipril for the Treatment of COVID-19
A Phase 2 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT04366050 is a Phase 2 study that has completed, run by University of California, San Diego. The registered enrollment target is 160 participants.
The verdict
NCT04366050, a Phase 2 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
In this study we propose to treat 560 patients with ramipril or placebo for 14 days. After an initial evaluation for COVID-19 status, medical history, and symptom assessment, patients will receive either 2.5 mg/day of ramipril or placebo. Patients' symptoms and study endpoints will be monitored at regular intervals. After 14 days, patients will undergo a laboratory assessment and an end-of-treatment follow-up visit at day 28. The primary endpoints of successful therapy will be improved survival, reductions in ICU admissions, and/or reductions in use of mechanical ventilator support.
Interventions
- DRUG Placebo oral capsule
- DRUG Ramipril 2.5 MG Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2020-05-11 |
| Est. Completion | 2021-05-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04366050
The ClinicalTrials.gov registry entry for NCT04366050 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT04366050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04366050 about?
NCT04366050 is a clinical study titled "Ramipril for the Treatment of COVID-19". In this study we propose to treat 560 patients with ramipril or placebo for 14 days. After an initial evaluation for COVID-19 status, medical history, and symptom assessment, patients will receive either 2.5 mg/day of ramipril or placebo. Patients' symptoms and study endpoints will be monitored at r...
What is the current status of trial NCT04366050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2020-05-11. Estimated completion is 2021-05-12.
What interventions are being tested in trial NCT04366050?
The interventions under investigation include: Placebo oral capsule (DRUG), Ramipril 2.5 MG Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT04366050?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.